NAD precursors, evidence snapshot: NMN, NR, niacin, and what human trials measured

The NAD biology, briefly

Nicotinamide adenine dinucleotide is a redox cofactor central to oxidative phosphorylation, and it is also the substrate for NAD-consuming enzymes including the sirtuins, PARPs, and CD38. Tissue NAD levels decline modestly with age in some animal and human cross-sectional data, and CD38 expression rises with age. The combination drove the modern interest in NAD precursors as a way to support tissue NAD levels.

There are several precursor pathways. Nicotinic acid (niacin) and nicotinamide are the original pathways. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are intermediates further along the salvage pathway. The pathway choice matters because the rate-limiting steps differ.

What the human trials actually measured

• Whole-blood or peripheral-blood-mononuclear-cell NAD concentration. NR and NMN both raise this in randomized controlled trials, on a roughly dose-dependent basis.
• Tissue NAD content via biopsy. Smaller and harder to do; the data are sparser and the effect sizes more variable.
• Surrogate metabolic endpoints (insulin sensitivity, lipid panels, blood pressure). Trial results have been mixed and small in magnitude.
• Functional endpoints (grip strength, walking speed, VO2max). Few trials are powered for these, and the published results have been mostly null.

The most consistent finding across NMN and NR trials is that they raise blood NAD. Whether that translates into the clinical and longevity outcomes the popular framing implies is much less established. The NIH Office of Dietary Supplements has summary materials on the broader B-vitamin family that contextualize the NAD precursor story .

Regulatory status, in 2026

NMN sits in a complicated FDA posture. The agency notified industry that NMN had been authorized for investigation as a new drug, which placed it outside the dietary supplement definition for new ingredient submissions. NR is widely sold as a dietary supplement under different commercial brands. The PubMed clinical-trial landscape covers both compounds .

What this changes for readers

If a reader is interested in NAD precursors as a longevity strategy, the honest current framing is that human RCTs have shown reliable elevation of blood NAD, weak and inconsistent metabolic effects, and no demonstrated effect on hard outcomes. That is not a verdict that the strategy fails. It is an accurate summary of what has been measured.